Dr Fouzia Andleeb
MBBS,MRCP,FRCR, Consultant Clinical Oncologist
Languages spoken
English
Overview
Content needed
Dr Fouzia Andleeb, MBBS, MRCP, FRCR, is a Consultant Clinical Oncologist at GenesisCare Oxford and Oxford University Hospitals NHS Foundation Trust, specialising in neuro-oncology and lung cancer. She has particular expertise in the non-surgical treatment of brain and spinal cord tumours, including benign and malignant brain tumours, brain metastases and skull base tumours.
Dr Andleeb’s practice encompasses chemotherapy and the full range of radiotherapy techniques across neuro-oncology and lung cancer, alongside immunotherapy for lung cancer. Her radiotherapy expertise includes conventional radiotherapy, stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT), stereotactic ablative radiotherapy (SABR) and reirradiation. She tailors treatment to each patient’s diagnosis, individual needs and priorities.
Alongside her clinical practice, Dr Andleeb is actively involved in research and has published work in neuro-oncology and lung cancer
.svg){kind=icon}
Career Positions
Current position(s)
- Consultant Clinical Oncologist, GenesisCare Oxford
- Consultant Clinical oncologist NHS
Expertise and interests
- Non-surgical management of CNS (Brain, spine) tumours, malignant and benign, including radiotherapy, chemotherapy, SRS, SRT, FSRT
- Non-surgical management of lung cancer, including radical radiotherapy, chemotherapy and SABR
- SRS, re irradiation
- Thoracic radiotherapy including Lung SABR
- Palliative radiotherapy
Professional associations
- Fellow Royal College of Radiologists (UK)
- Society of Neuro-Oncology
- British Society of Neuro-Oncology
Publications & affiliations
- Unilateral vs Bilateral Radiotherapy in Oral Cavity Cancer
Presented at the Liverpool Head and Neck Centre (LHNC) Clinical Study Day, December 2019. - Role of PET-CT in Head and Neck Cancer
Presented at the Liverpool Head and Neck Centre (LHNC) Clinical Study Day, December 2018. - Afatinib Dose Intensity and Clinical Efficacy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: UK Multicentre Real-World Data
Participated in the study. Poster presentation at the ESMO Congress, October 2018. - QIP Criteria for Cardiac Assessment/Echocardiography Prior to Chemotherapy for Breast Cancer.
- Comparison of Responses After 2 vs 4 Cycles of First-Line Palliative Chemotherapy in Stage IIIB and Stage IV NSCLC
Completed at the Beatson Cancer Centre in June 2013. Abstract accepted for poster presentation at the IASLC 15th World Conference on Lung Cancer, Sydney, Australia, October 2013. - SRS Re-irradiation Audit
Presented at the BRSS, 2024.